Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Relacorilant by Corcept Therapeutics for Cushing's Syndrome: Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase III for Cushing's Syndrome. According to GlobalData, Phase...
Relacorilant by Corcept Therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
Relacorilant by Corcept Therapeutics for Prostate Cancer: Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
Mifepristone by Corcept Therapeutics for Alcohol Dependence: Likelihood of Approval
Mifepristone is under clinical development by Corcept Therapeutics and currently in Phase II for Alcohol Dependence. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Corcept Therapeutics's Relacorilant?
Relacorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase III program in Cushing's Syndrome. According to...
Zavacorilant by Corcept Therapeutics for Alzheimer's Disease: Likelihood of Approval
Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...
Zavacorilant by Corcept Therapeutics for Huntington Disease: Likelihood of Approval
Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Huntington Disease. According to GlobalData, Phase...
Zavacorilant by Corcept Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Corcept Therapeutics's Dazucorilant?
Dazucorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase II program in Amyotrophic Lateral Sclerosis. According...
Risk adjusted net present value: What is the current valuation of Corcept Therapeutics's Miricorilant?
Miricorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase II program in Obesity. According to Globaldata,...
Mifepristone by Corcept Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Mifepristone is under clinical development by Corcept Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...